Good afternoon, and welcome to Revenio Q3 earnings call. My name is Jouni Toijala. I am the Group CEO, and then again today, we have Jukka Kainulainen, our CFO, in a call, of course, as well. Today's agenda is following. I am starting to recap the Q3 from the financial summary point of view. Then, let us also spend a bit time where we have been spending time during the Q3 and how the things like integration, all the other topics have been going forward during the Q3. Then, Jukka is going to continue by going through the financials, then also, of course, the guidance. Then we move for the Q&A. Q3, in all aspects, historic quarter for Revenio. During the Q3, we have doubled our scale. We have kicked off the integration, of course.
If you look from the pure numbers perspective, net sales EUR 58.8 million during the Q3. If you look the reported numbers perspective compared to old Revenio, the growth is roughly bit less than 130%. We have been also increasing the transparency when it comes to the reporting the numbers, region-based numbers. We had an extremely strong growth in our largest region, which is EMEA LATAM, and ending up to EUR 34.3 million. If you look the other regions, like APAC, that during the Q3 remained to be still soft. We have been focusing in the U.S.A. Our organization changed, especially on the sales and marketing side. I will come back to that one. We had a slight decline year-on-year if you compare to the pro forma in the U.S.A., but I will come back for that one.
The reason for that one is that we reorganized the whole sales and marketing organization in order to be able to provide a long-term sustainable growth also in the U.S.A. Adjusted EBITDA EUR 8.7 million, so compared to last year, that is a 30% increase. Also, we started to be now way stronger in terms of the cash flow, so EUR 5.5 million up from EUR 3 million. We are advancing the integration as planned, even a bit more faster schedule what we originally planned. So far we have been able to secure from the run rate basis 25% of the targeted EUR 20 million EBITDA uplift. Regarding the Q3, the focus of the organization has been really building the base for the long-term sustainable growth.
If we go and look back the old Revenio, where we were selling tonometers, fundus imaging devices, perimeters, probes, plus the software solutions like ILLUME. Now the company is totally different, and the priorities are totally different. During the Q3, we have been, of course, clarified the new combined company strategy. We communicated that during the CMD. If you recall, the strategy is geared around leading the shift from vision care to the connected eye health. Then we have put the totally new organization operative model in place. Here I want to emphasize the big revamp of the organizations in the U.S.A. That includes all the functions and, of course, especially the U.S. sales and marketing department. We organized the whole team now in a totally different way to the three regions. Then new team members in also there.
So, of course, that's a self-evident that it's having a slight impact also to the sales performance in the U.S. But why we did this one is, of course, that it enables us to grow then in a long run. Then third topic is what I mentioned already regarding to the organization and related changes there, which are then, of course, having an impact to the OpEx side, especially in the U.S. So we have been able to advance the integration extremely well on that front. As of today, looking the Q4, so we still have actions ongoing regarding to the OpEx activities, but bit by bit, the focus is starting to move more towards the harnessing the commercial synergies.
Then, our net debt EBITDA ratio was quite high, bit over five, so we have been working, of course, during the Q3 to secure the rights issue, which was oversubscribed, so that went well. After the review period, also the leverage is now reduced to the bit more than three, but Jukka is coming back to this one. If we now start to look the Q4, start to look where the focus currently is, so we still have on our plans, we have activities and actions regarding to the OpEx synergies, but we are shifting a bit more now also the focus to harness the forthcoming commercial synergies. What I mean with this one is that we already have clear, active cross-selling plans in place, starting to execute those ones. We have plans how to optimize the sales channels globally, so the U.S. part is done.
Then, of course, putting more emphasis on key account coverage as we now have a way more wider product portfolio. With all these actions, we really have a feeling that we are having a good momentum for 2027 as well. Then we have been discussing as well quite many times in these calls that are there any new products coming, how we are allocating the capital, and this is the latest case on that front. So during the Q3, we launched a new iCare tonometer called IC1000. Extremely well received among the distributor partners and then, of course, our clinical clients. So we introduced the GuideCam alignment, so you have an excellent alignment feature, including the full-on automation and the camera on the screen.
Then, of course, the SmartCradle to be able to plug in wirelessly to the clinical workflows and all the same tech which used to be still on the old ones. So it's anesthesia-free and, of course, uses the rebound tech and is going to long run also enable the increased consumable sales. Then if we also look the future, so the strategy is not going to change. So in the product categories, what we have now as a combined company, so we are going to continue to invest also in the future to the R&D in order to bring the new innovations in the market. But this is the latest which we launched during the Q3. But hey, let's jump to the financials. So over to you, Jukka.
Thank you. Thank you, Jouni. As a reminder, of course, this is the first quarter when we have whole Visionix in our numbers starting from the beginning of the quarter, because quarter two we had only one month in our numbers. When looking the net sales and net sales growth with the reported numbers, like Jouni highlighted, almost 130% growth. So net sales has more than doubled when you look the quarterly numbers. Also, when looking the year-to-date numbers, EUR 125 million net sales also growing almost 60%. So scale is totally different, and also when looking the companies and comparables, quite different company nowadays than one year back, as you see.
When looking the profitability metrics, going to adjusted EBITDA, EUR 8.7 million compared to EUR 6.6 million, quarter 3 2025, 14.7% of the net sales when in comparables it was 25.7%. It is good to note that in absolute terms, this adjusted EBITDA is more than 30% up when looking the real euros. So the new scale is also seen in our earnings line. When looking the leverage metrics, balance sheet metrics, equity ratio 32%, gearing 149%, and this is of course before the rights issue took place in October because we report the quarter three numbers. Still sequentially also the leverage metrics were improving and balances strengthened between the quarters. So that is really, really relevant as well. Let us go more in details to the net sales and net sales growth.
Quarter three net sales EUR 58.8 million, and when we look it organically, and that means when we compare it for the pro forma for combined company last year, quarter three 2025, our growth was basically flat when looking quarter three, looking year to date. When looking under the numbers, different regions, we had a really strong performance in EMEA and LATAM. When we looked at organically, it had a really strong growth driven by the big countries, Italy, France, and our global customers as well, and supported by this multimodal offering we have overall. Like Jouni highlighted, the challenging market environment has continued in the APAC region, and in the North America, the reorganization we did impacted on the sales numbers during the quarter three 2026.
Let us look more in details our profitability and adjusted EBITDA, starting maybe first on the gross margin. So gross margin declined to 63.2% compared to 71.5% one year back, and it has a 9% point dilution impact coming from the Visionix lower margin profile. So now we have Visionix in whole quarter numbers, and that is visible also in the gross margin numbers as you see. A few other items impacting our profitability and gross margins. Still the unit cost increases regarding the electronic components had the negative impact on our gross margin overall and also our sales mix. So those two together had around 2% point negative impact on the gross margin.
But then at the same time, we had a positive impact coming from the North America business, and tariff refunds over there had around 3 percentage points positive impact on our gross margin for the quarter. Like I highlighted previously, adjusted EBITDA EUR 8.7 million for the quarter and EUR 6.6 million in the comparable period. Roughly more than 30% up in earnings when looking the adjusted EBITDA line. Then let's move the cash flow. Cash flow from operating cash flow turned positive for the quarter three, EUR 5.5 million, and improved from the last year reported numbers in quarter three, EUR 3 million. That was driven by the strong working capital development during the quarter. Even though it included around EUR 2 million one-off payments regarding our integration, which is of course ongoing.
Then when looking more in details the balance sheet, and of course the balance sheet metrics is reflected by the Visionix acquisition. When looking the quarter three end situation, term loan of EUR 130 million, vendor loan of EUR 17 million, and at that moment we still had the bridge-to-equity facility EUR 80 million. Around EUR 232 million net debt at the end of the quarter three. But still our net gearing improved from 159% end of quarter 2% to 149%, and also equity ratio went up from the 31% end of quarter 2% to 32%. Cash, we had cash balances EUR 17 million at the end of the quarter. Also this net debt adjusted EBITDA went also down from 5.3 end of quarter 2 to 5.1.
All the balance sheet metrics improved even though this rights issue was not completed when we look the end of the September situation. When we look it as of now, during the October, we were able to close the rights issue, which was fully oversubscribed. By the way, thanks for everyone who joined on the rights issue. We have already, as of today, paid out also bridge-to-equity facility of EUR 80 million. But of course, when we report here the quarter three numbers, those are not yet visible here. Overall, we of course continue our profitable growth. We improve also our cash flow, which will improve the leverage metrics also for the coming quarters and going forward. Then regarding our shareholders register at the end of the September, maybe few highlights here regarding also the Visionix acquisition.
There is few new names in the table coming from the France, Caravelle Capital as new owner owning more than 5% of the company. Also, Marc Abitbol became the owner owning 1.5% of the company regarding the Visionix acquisition. Of course, overall, we have almost 50% of our owners outside Finland, which is quite a good number for the listed company overall. Then let's go to our financial guidance. We have specified our financial guidance regarding the net sales, and we have narrowed down our top end of the guidance. Our previous financial guidance for the net sales was between EUR 190 million up to EUR 205 million.
Our specified guidance is between EUR 190 million up to EUR 200 million. Regarding profitability guidance, that is unchanged. The changes are coming from the regional impacts. Like we commented, strong performance in EMEA and LATAM, but we had the reorganization in North America impacting our sales in Q3, and the challenging market environment continues in the APAC region. All these are reflected in our new guidance. Thank you.
Thank you, Jukka. Let's move to the questions, please.
If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Nikko Ruokangas from SEB. Please go ahead.
Hello, this is Nikko Ruokangas from SEB. Thank you for the presentation. I have a couple of questions. First of all, I wonder if you can give us a bit more color on organic growth. Were sales flat both in old Revenio and Visionix, or were there big differences? At least you hinted in Q2 call, which was quite late already in Q3, that Revenio organic growth had started to pick up. Can you give a bit more color on that, please?
As you actually said, Nikko, both flattish. Here I want to emphasize the logic. We did a fundamental change in the U.S.A., like Jukka said. Strong growth in Europe, Middle East, Africa, LATAM. Strong growth there. The APAC remained a bit more softer. Then we reorganized the whole U.S. sales and marketing. We changed the region setup. We changed even the kind of scope of the area for the sales teams. We introduced the combined product portfolio. We cross-trained the U.S. sales and marketing team to sell and market the full new combined company product portfolio. That's the logic, and happy to see that it was only minor slice. We prioritized this activity right away after the 60 days. The new organization setup was in place beginning of August.
The reason why we prioritized this one was all the other U.S.-specific activities to guarantee successful start for the integration, getting the EUR 5 million run rate EBITDA uplift in terms of the OpEx, and then gearing for the future growth. We would have been able to perform better in the U.S.A. from the sales perspective if we wouldn't have changed anything. But that wouldn't be positive for the long-term sustainable growth in the U.S.A. Sorry for the long answer, Nikko, but I think this is crucial to understand and still building what I was saying, that Revenio is now totally different than it used to be before, or kind of during the big part of the Q1 and almost the whole Q2. We are totally different company.
The focus for Q3 hasn't only been how do we maximize the organic growth for tonometers, how do we maximize the organic growth for imaging and perimetry. The focus has been that how do we create a combined company strategy, how do we create and specify new organization and operative model, how do we take care that the rights issue is going to be successful, and how we kick off the promised EUR 20 million synergy activities in. Happy to see that in this big shift and the big integration what we started, we are on, in a way, flat. The benefit is that then we have been able to get the first EUR 5 million in terms of the synergies. Sorry, Nikko, for the long answer, but I think this is a big picture how we see this one internally at Revenio.
Yeah. Thanks. This was very good. I see it's reasonable. Does it mean that the negative impact came quite late in Q3? Then should we kind of expect that to still to continue in Q4, or how have you kind of planned that?
Yeah, I would say so in terms of the U.S.A. We planned kind of during the Q2. Then we started to execute during June, July, and then your new team was in place, meaning sales and marketing, finance, control, HR. The whole new U.S. team was in place then starting August 1. Then the team has been working to, of course, build the plans and continue on sales, continue on customers, et cetera. This has been the timing.
Okay. Understand. Thanks. Then on the larger customers you have mentioned you have in pipeline. Have you kind of been recognizing any of those as sales yet? Was this NHS you mentioned in the report one of those that were in the pipeline? Can you give a bit more color and update on the large customer pipeline?
Yeah. That deal was in a pipeline. Then, of course, we had a couple of other deals. Those have been moving forward and then bit by bit starting the rollout then towards early 2027.
Okay. So the NHS deal, have you recognized sales from that in Q3? If not, can you give a bit color on when
No, we haven't recognized the revenue from the NHS deal for Q3.
Can you give any color on the size or timeline?
No. No on the size, but bit by bit starting to receive the orders.
Thank you. Then last from me at this point. On tariff refunds, you indicated, I guess, some EUR 2 million you received in Q3. Can you open a bit more from which period did you receive those? Were they tariff payments from early 2026, or do this include also tariff payments from 2025? Have you kind of received all the tariff repayments you will receive overall as of end of Q3, or should we expect more still in Q4?
Yeah. What I can comment is that, yeah, it was earlier periods, tariff refunds, and then we, of course, work constantly to get more of those refunds. But there is always big uncertainty regarding those, so we do not plan, we do not forecast it internally, when we kind of achieve it or when we succeeded it. This is the level we can comment it. But it was really great to get it during the Q3.
All right. Great. Thank you. That is all from me at this point.
Thank you, Nikko. Thank you.
The next question comes from Daniel Lepistö from Danske Bank. Please go ahead.
Hi, it's Daniel Lepistö from Danske Bank. I also have a couple of questions. Maybe starting off with the guidance, which you cut the top line a little bit. I am a bit curious about where the negative delta came from. Was it this reorganization that happened in North America? Did it go as you planned, or was it about these larger deals slipping forward? Can you dissect this guidance top line cut a little bit?
Maybe Jukka comments a bit more further, but I think what we have been now trying also to improve, based on the feedback what we have got, is that we usually have been guiding the top line based on the objective, and then bottom line based on the objective. Now we included the EUR bracket for that one, and now we then also now trying to be more specific when the year goes towards the end so that the transparency increases. I think this is an underlying logic why now having a bit more narrower, and maybe you, Jukka, comment-
Yeah, and then-
Comment on-
Yeah.
Yeah, like we commented, the APAC region continuing challenging situation, impacting the sales also in Q3, and also this North America reorganization, and that impacts on our sales in H2. Those were the impacts driving down the top end of the sales guidance.
Okay. Then maybe still on this reorganization. Just to clarify, are you seeing any risks what comes to this seasonally very important Q4? Are you seeing any risks with this reorganization impacting maybe the Q4 numbers still?
Not from the reorganization point of view, and that was also the reason that why we moved really fast by reorganization, or by reorganization the teams globally, also in the U.S., and putting everything in place in order to be efficient and ski straight for Q4. I have to say and emphasize here that the organization change in the U.S. and in other parts, it has been going extremely well, extremely smoothly. No key people has left, and we have a U.S. team fully functional already now almost two months. No worries on that one. Everything has went well, but of course, it has an impact to activities. To sum up still and emphasize that from the reorganization point of view, house is in very good order for Q4.
Okay, that is good. Then on the gross margin, on this component, impact to the gross margin. Is this going to roll over, or has the situation worsened, or is this going to remain intense? How would you characterize this component issue?
Yeah, so far, of course, will impact also during the quarter four at least. Next year, we cannot, of course, comment, but will continue also during the end of the year.
Okay, that is clear. Then final question on this CapEx. Can you give us a little bit of help with the, what kind of underlying CapEx run rate should we think for this combined entity going forward? Then on this one-off IT costs that will be CapEx items, so when are these going to materialize?
Yeah, so of course, the CapEx is now slightly higher, even though on the reasonable level, but due to Visionix, we have also the real manufacturing, so that is driving the level up. But you can use the quarter three as a baseline in your planning overall. What was the other question you had?
On this one-off IT costs.
Yeah, so at the moment, we are not planning to capitalize the one-off costs or integration-related IT costs.
Is it something for maybe 2027?
Yeah, 2027, that will be part of our integration, the IT-related OpEx investments we do.
Okay. That is all from me. Thank you.
Thanks, Daniel.
The next question comes from Pia Rosqvist-Heinsalmi from DNB Carnegie. Please go ahead.
Hello, this is Pia Rosqvist-Heinsalmi from DNB Carnegie. Thank you for taking my questions, and thank you for the presentation, and really good questions from my analyst colleagues. Just to clarify, as of now, do you see a risk of that your reorganization elsewhere will impact sales as negatively as it did in the U.S. now in Q3?
No. I think we have to remember the slight differences now, if you think the U.S.A. and remaining part of the geographies. We had, at old Revenio, we had a direct sales force plus the reps, which are on our control. Same for Visionix. That needed to be reorganized right away in order to be fit for long-term growth in the U.S.A. In order to sell the combined portfolio, we needed to do the cross-training in order to enable and do the cross-sales plans and have a combined company approach right away to address these big customer accounts. Then if you go for the other parts of the region, Europe, Middle East, Africa, LATAM, we go for APAC. That's a combination of distributors, both from Visionix, both from ex-Revenio iCare side, and then also these direct countries.
In a way, from the sales perspective, it's a way more natural setup, and it's not as kind of complicated to handle. What's going to happen there? We have done already certain alignments inside the direct countries, having plans how to more efficiently work with distributors, consolidating certain distributors or changing them based on the plans. Then, I think it's good to understand it's a bit more different setup in other parts of the world compared to the U.S.A. In one sentence, we have good plans now also in other parts of the world, and those are on the execution.
All right. Thank you. Then, regarding your cross-selling wins, have you started to see some kind of cross-selling wins now already in Q3?
Not yet too much on Q3, but the pipeline building, yes. I think that's a key to understand that we started to build the, of course, build the pipeline and then doing the cross-training in the areas where it's needed. Of course, planning the cross-sales activities.
All right. Thank you. In the report, you shared some rough numbers or sales split on pro forma sales for 2025 by product line. Regarding that, I would like to understand the OCT sales you refer to. What does that contain, and are there any overlaps in that OCT category with, for example, the imaging devices?
Yeah, so that is the OCT sales and the product line we got in connection to Visionix acquisition. Maybe, you know, Jouni can comment regarding the overlaps with our old iCare imaging product.
Yeah, no, so that is a pure OCT business, no overlap with the ex-iCare imaging business.
All right. Thank you. I think in conjunction with the acquisition, you also explained that part of Visionix's sales were OEM sales, right? How does that fit? Can you share some more information about the OEM sales? What kind of products does that involve?
Yeah, so the big part on that front is the VX 650, the multimodal devices. That part, still the OEM business, is going to continue to be in our focus. The reason is that the clients are extremely big players who are bundling the multimodal devices, as an example, with IOLs or so forth. That is still going to be good and significant business for us also in the long run. Those are the customers that we are not able to get in, so quite a lot of bundle deals with the IOLs, as I said, and links to the multimodal side of the business.
All right. That is all for now. Thank you.
Thank you, Pia. Thank you.
The next question comes from Joni Sandvall from Nordea. Please go ahead.
Yeah, thanks. Joni Sandvall from Nordea. A couple of questions also from my side. Any update on your ILLUME FDA approval process and related costs? When should we expect this to happen?
Yeah, pivotal studies we have done. Bit fine-tuning now the algorithm, looking to start the clinical studies on that front. Costs 2027, I think we are sliding towards the Q3, Q4 2027 with the approval, so timing slightly sliding forward. On the positive note, now we have a DRSplus approved together with the iHealthScreen algorithm. So, in a way, we are good to go in the U.S.A. when it comes to DR screening. But then, of course, the software partner is different compared to our own because it's an iHealthScreen. That's currently the status on that side.
Okay, thanks. Then maybe a couple of technical questions for Jukka. Net financials were at break-even. Could you open up a little bit logic behind this, and what is actually your current average interest rate on the loan portfolio?
Yeah. Real interest cost quarter three was EUR 1.8 million, but then we also have this interest rate swap for the term loan, so half of that has been hedged. So that has quite a big positive impact now in quarter three. So, came more than actually EUR 1.4 million positive impact. Then also we have a intercompany loan in USD from our entity in Europe to U.S., around $30 million, so that had a positive impact as well. That's why it looked quite good when looking at the finance income and expenses.
Okay, that's clear. On the deferred tax assets, what you have in the balance sheet, should we expect the effective tax rate to remain low in Q4, and how you expect this to evolve in 2027?
Yeah, this is something we work at the moment, overall the transfer pricing, which is impacting on the tax rate. Of course, overall, we will, of course, try to keep it competitive also for the next year. I cannot foresee any changes for Q4 or next year, but this is something we work constantly in a company level.
Okay, thanks. That's all from me.
Thank you, Joni.
Thank you.
There are no more questions at this time, so I hand the conference back to the speakers.
Maybe there is one more question.
The next question comes from Nikko Ruokangas from SEB. Please go ahead.
Hello. Thank you. This is Nikko Ruokangas again. One more additional question on the cybersecurity issue you reported earlier this week. Just if you can give comments on what are the kind of implications? Does it have any kind of financial or operational impacts to you? Do you see any kind of a need for further investments into Visionix cybersecurity in the software platform? Thanks.
Yes. Entry to one internal server, which was not including any IP or any that kind of a level thing, no patient data, no nothing. The case is already in order. If we look the hardening things and to improve the cybersecurity, that was already baked into the integration plan to strengthen up the Visionix cybersecurity and IT infrastructure. Those costs are kind of already baked into the original plan.
In one sentence, yes, someone got in one server, no impact to the operations, no impact to the financial performance, and no loss of IP. In that sense, house is in order. We wanted to be transparent on this one so that you hear it from us first and not including any rumors. That was also the logic why we put the press release out and, of course, why it was not the stock exchange release, because we don't see a big impact on this one. That's the background and that's the logic for the press release.
Nikko, like all the companies, we also definitely cybersecurity really critical point and high on the agenda. Of course, we'll continue investing on that to have a strong environment over there and good processes as well.
Okay, thank you. That was a good answer opening it and sounds reasonable. Good to hear. Thank you.
Thank you, Nikko.
Thank you.
There are no more questions at this time, so I hand the conference back to the speakers.
Thank you very much for your time. Thank you for the excellent questions, and have a nice autumn. We come back after the Q4 is ready. I think, Jukka, right, so it is a bin of, or kind of a mid of February.
Mid or end of February.
Yes.
We will communicate it out through the stock exchange release.
Thank you all. Have a good rest of the day.